HCW Biologics News - August 14, 2026
HCW Biologics second quarter 2026 loss hit $5.2M despite $6.7M year-to-date licensing revenue
HCW Biologics reported second quarter 2026 revenue of $0.14 million and a net loss of $5.2 million. While year-to-date performance was bolstered by a...
HCW Biologics to Restate Q1 2026 Financials, Overstated EPS by $0.80
HCW Biologics announced that its previously issued financial statements for the first quarter ended March 31, 2026, should no longer be relied upon due to a...
🔴 HCW Biologics is trading 7.35% down today as the cause remains unclear
HCW Biologics is trading 7.35% down at $2.71, with no confirmed company-specific catalyst identified. - The stock declined from $2.92 on August 13, 2026. - No...
🟢 HCW Biologics is trading 6% up today with no confirmed catalyst
HCW Biologics is trading 5.98% up now at $3.10, with no confirmed company-specific catalyst identified for August 14, 2026. - The move follows a 7.00% decline...
🟢 HCW Biologics is trading 19.66% up in pre-market — no confirmed catalyst identified
HCW Biologics is trading 19.66% up at $3.50 in pre-market, with no confirmed company-specific catalyst identified for August 14. - The stock fell 7.00% to...
🔴 HCW Biologics is trading 7% down in pre-market with no confirmed overnight catalyst
HCW Biologics is trading at $2.72, down 7.01%, with no confirmed company-specific announcement or earnings release identified to explain the August 14...